secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001104659-24-117243
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics Q3 net loss $9.9M; CT1812 slows decline 95% in Alzheimer's sub-group
--------------------------------------------------------------------------------

- Net loss $9.9M ($0.25/share) vs $6.7M ($0.22/share) in Q3 2023; cash $22M plus $53.6M NIA grants.
- CT1812 showed 95% slowing of cognitive decline (ADAS-Cog11) in Alzheimer's patients with low p-tau217 at CTAD.
- On track to report Phase 2 SHIMMER topline results in dementia with Lewy bodies by end of 2024.
- Plans to request end-of-Phase 2 FDA meeting for CT1812 Alzheimer's program.
- Cash runway into Q2 2025; R&D expense $11.4M, G&A $3.1M both flat YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465924117243/0001104659-24-117243-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465924117243/tm2428074d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-117243

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer